GlennLiuMD

Oncology • Madison, WI

Genitourinary Oncology

Professor of Medicine and Medical Physics, University of Wisconsin School of Medicine and Public Health School

Join to view full profile

Dr. Liu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Liu's full profile

Already have an account?

Office
1111 Highland Ave
WIMR 7051
Madison, WI 53705
Phone+1 608-265-8689

Fax+1 608-262-1982

Summary

Glenn Liu, MD is a Professor of Medicine and Medical Physics at the University of Wisconsin. He is the Head of Genitourinary Oncology in the UW School of Medicine and Public Health, and Director of Genitourinary Oncology Research and Leader of the Developmental Therapeutics Program at the UW Carbone Cancer Center. Dr. Liu is the chair of the Prostate Cancer subcommittee for ECOG-ACRIN. He is also a co-founder of AIQ Solutions, which is a UW spin-off company based in Madison, WI.

Education & Training

University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 2000 - 2002
University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1997 - 2000
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1997

Certifications & Licensure

WI State Medical License 1998 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Ixabepilone in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2004 Sep 01
Completed
Phase 2
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2006 Sep 26
Active, not recruiting
Phase 3
Efficacy and Pharmacodynamic Study of Panzem® NCD in Patients With Hormone-Refractory Prostate Cancer Start of enrollment: 2006 Nov 01
Completed
Phase 2
Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2007 Feb 01
Completed
Phase 2
Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors Start of enrollment: 2007 May 22
Completed
Phase 1
Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer Start of enrollment: 2003 Aug 01
Terminated
Phase 2
Phase 1 Study of MKC-1 in Patients With Advanced Cancer Start of enrollment: 2008 Mar 01
Completed
Phase 1
Pharmacodynamic Study of Axitinib in Patients With Advanced Solid Malignancies Start of enrollment: 2009 Feb 01
Completed
Phase 1
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
ZD4054 With Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) for Prostate Cancer Start of enrollment: 2010 Apr 01
Terminated
Phase 2
Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies Start of enrollment: 2010 Oct 01
Completed
Phase 1
Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy Start of enrollment: 2011 Jan 01
Completed
Phase 2
Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Microtubule Directed Chemo or AR-directed Therapy Start of enrollment: 2011 Nov 01
Completed
Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib Start of enrollment: 2012 Mar 01
Completed
Phase 1
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2012 Mar 30
Completed
Phase 2
Study of 124I-NM404 in Advanced Solid Malignancies Start of enrollment: 2012 Jul 01
Terminated
Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer Start of enrollment: 2013 May 20
Completed
Phase 2
A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Start of enrollment: 2011 Dec 01
Completed
Phase 2
Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone. Start of enrollment: 2015 May 01
Completed
Phase 2
Imaging Biomarkers to Validate Response in Enzalutamide-Treated mCRPC Start of enrollment: 2016 Jun 27
Completed
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer Start of enrollment: 2013 Feb 01
Recruiting
Join now to see all

Publications & Presentations

PubMed

Long-term follow up of patients treated with a DNA vaccine (pTVG-hp) for PSA-recurrent prostate cancer.
Tommaso P Tonelli, Jens C Eickhoff, Laura E Johnson, Glenn Liu, Douglas G McNeel
Human Vaccines & Immunotherapeutics. 2024-12-31
Digital Pathology-based Artificial Intelligence Biomarker Validation in Metastatic Prostate Cancer.
Mark C Markowski, Yi Ren, Meghan Tierney, Trevor J Royce, Rikiya Yamashita
European Urology Oncology. 2024-12-10
7 citations
Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer.
Douglas G McNeel, Hamid Emamekhoo, Jens C Eickhoff, Christos E Kyriakopoulos, Ellen Wargowski
Journal for Immunotherapy of Cancer. 2023-12-14

Lectures

Randomized phase II trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) versus GM-CSF adjuvant in patients with PSA-recurrent prostate cancer.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Carbone Experts Present Latest Research at World's Largest Cancer MeetingMay 31st, 2019
UW Carbone Cancer Center Researchers Win Two National Prostate Cancer AwardsAugust 24th, 2017
Madison Vaccines Announces First Patient Dosed in an Expanded Combination Trial of MVI-816 plus Keytruda® for Metastatic, Treatment-Resistant Prostate CancerAugust 2nd, 2017
Join now to see all